(MedPage Today) — Potential for macular degeneration adds to Alzheimer’s disease worries with Entresto
Uncategorized
Ocular Therapeutix™ Announces FDA Acceptance of NDA Filing for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the New Drug Application (NDA) for DEXTENZA™ (sustained release dexamethasone), Intracanalicular Depot, for the treatment of ocular pain following ophthalmic surgery, has been accepted for review by the U.S. Food and Drug Administration (FDA). The acceptance of t
Uncategorized
Resumen: Novaliq GmbH nombra a Friedrich von Bohlen, PhD, presidente, y a Gerald Cagle, PhD, nuevo miembro del consejo de administración de Novaliq
HEIDELBERG, Alemania–(BUSINESS WIRE)–Novaliq GmbH, empresa farmacéutica especializada en estudios clínicos con una plataforma de suministro que transforma medicamentos poco solubles en terapias oftalmológicas efectivas, ha anunciado hoy que Friedrich von Bohlen, PhD, ha sido nombrado presidente del consejo de administración y que Jerry Cagle, PhD, se ha unido al mismo como miembro. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un
Ignyta Announces Initiation of STARTRK “Next Generation” Phase 1/1b Pediatric Clinical Trial of Entrectinib
SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the initiation of STARTRK-NG, a new pediatric Phase 1/1b clinical trial of entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK. STARTRK-NG (which stands for “Studies of Tumor Alterations Responsive to Targeting Receptor Kinases – Next Generation”) is a multicenter, open
Why focusing on a visual task will make us deaf to our surroundings
Concentrating attention on a visual task can render you momentarily ‘deaf’ to sounds at normal levels, reports a new UCL study funded by the Wellcome Trust.
Portable device can quickly determine the extent of an eye injury
An engineer and an ophthalmologist are developing a portable sensor that can quickly and inexpensively determine whether an eye injury is mild or severe.